|
Originally published In Press as doi:10.1074/jbc.M109678200 on November 19, 2001
J. Biol. Chem., Vol. 277, Issue 6, 4232-4239, February 8, 2002
Membrane Association of Glutathione S-Transferase
mGSTA4-4, an Enzyme That Metabolizes Lipid Peroxidation
Products*
Sharda P.
Singh ,
Andrzej J.
Janecki§,
Sanjay K.
Srivastava¶ ,
Sanjay
Awasthi**,
Yogesh C.
Awasthi¶,
Shujuan J.
Xia , and
Piotr
Zimniak  §§
From the Departments of Internal Medicine and
 Biochemistry & Molecular Biology,
University of Arkansas for Medical Sciences, and Central Arkansas
Veterans Healthcare System, Little Rock, Arkansas 72205; the
§ Department of Internal Medicine, University of Texas
Medical School, Houston, Texas 77030; the ¶ Department of Human
Biological Chemistry & Genetics, University of Texas Medical Branch,
Galveston, Texas 77555; and the ** Department of Chemistry
and Biochemistry, University of Texas at Arlington, Arlington, Texas
76019
Received for publication, October 5, 2001, and in revised form, November 14, 2001
 |
ABSTRACT |
Lipid peroxidation products have signaling
functions and at higher concentrations are toxic and may trigger cell
death. The compounds are metabolized predominantly by glutathione
S-transferases exemplified by mGSTA4-4, an enzyme
highly efficient in glutathione conjugation of 4-hydroxyalkenals, and
possessing glutathione peroxidase activity toward phospholipid
hydroperoxides. mGSTA4-4 belongs to the predominant group of
"canonical" glutathione S-transferases that are soluble
and generally localized in the cytoplasm. The intracellular
localization of mGSTA4-4 was examined in hepatocytes of normal mouse
liver and in transfected HepG2 cells by fluorescence microscopy and
digital deconvolution. mGSTA4-4 was found to be predominantly localized
at or near the plasma membrane in transfected HepG2 cells, as well as
in hepatocytes endogenously expressing the protein. In
vitro, mGSTA4-4 associated with liposomes, and this interaction
was potentiated when the liposomes contained negatively charged
phospholipids. Mutating lysine 115 to glutamic acid resulted in
a loss of the plasma membrane targeting of mGSTA4-4 as well as in a
significant reduction of its binding to liposomes in vitro.
These data suggest preferential targeting of mGSTA4-4 to the plasma
membrane that may contain the major substrate(s) for this enzyme.
Lysine 115 is critically important for the membrane association of
mGSTA4-4, most likely by entering into an electrostatic interaction
with negatively charged phospholipid headgroups.
 |
INTRODUCTION |
Lipid peroxidation is a detrimental outcome of oxidative stress.
However, in the course of evolution products of lipid peroxidation have
also acquired a physiological function: they signal the presence of an
oxidative insult and trigger an appropriate cellular response. Although
lipid hydroperoxides can act directly as messengers (1), the signaling
function appears to be associated primarily with downstream products
derived from hydroperoxides of polyunsaturated fatty acids. These
products, the highly electrophilic and diffusible 4-hydroxyalkenals,
including the predominant 4-hydroxynonenal (4-HNE)1 (2), were thought to
be formed in a spontaneous, non-catalyzed reaction, although recent
results indicate a possible involvement of enzymes in this process (3).
Because of their chemical properties as Michael acceptors, 4-HNE and
similar , -unsaturated aldehydes have the ability to modify
proteins (4, 5), often with considerable selectivity (6). Such
modifications of a number of key regulatory proteins result in specific
physiological outcomes, including effects on the cell cycle, cell
differentiation, and cell death (reviewed in Ref. 7).
Given the signaling functions and, at higher concentrations, the
toxicity of lipid peroxidation products, their metabolism is of dual
importance in detoxification and in signal termination. Phospholipid
hydroperoxides are substrates for selenium-containing glutathione
peroxidases (1) and for the glutathione peroxidase activity of
Alpha-class glutathione S-transferases (GSTs) (8-11). Of
these, the selenoenzyme Gpx4 (12, 13) and GSTs do not require prior
phospholipase action. It has been recently shown that Alpha-class GSTs
contribute the majority of activity for phospholipid hydroperoxides, at
least in some cells (10, 11). 4-Hydroxyalkenals are metabolized predominantly by conjugation to glutathione by a subclass of
Alpha-class GSTs exemplified by mGSTA4-4, which also possesses
glutathione peroxidase activity toward phospholipid hydroperoxides
(reviewed in Ref. 14). Early stress response is characterized by
increased lipid peroxidation and by induction of an Alpha-class GST
that conjugates 4-HNE (15). Thus, Alpha-class GSTs play a key role in
the catabolism of lipid peroxidation products.
Lipid peroxidation products either reside in membranes (phospholipid
hydroperoxides) or partition into membranes to a significant degree
(4-HNE). Strikingly, the Alpha-class GSTs responsible for the majority
of the metabolism of these compounds were not thought to be associated
with membranes. GSTs are ubiquitous enzymes with diverse functions
(16-18). At least three structurally unrelated groups of these enzymes
arose through convergent evolution: the canonical soluble GSTs,
microsomal GSTs, and the bacterial fosfomycin resistance protein
(19-21). The subcellular localization of the canonical GSTs, which
include the major mammalian Alpha, Mu, and Pi classes, has been studied
in several tissues (22-28). The enzymes are present mainly in the
cytosol. For several GSTs, especially of the Pi class, nuclear
localization has also been reported (22, 24-26), which is consistent
with a role in protecting DNA from damage by electrophiles and
oxidants. Mitochondrial localization has been reported for hGSTA4-4
(28) and for rGSTA4-4 (27), enzymes involved in the metabolism of lipid
peroxidation products (29, 30).
The goal of the present study was to examine the subcellular
localization of mGSTA4-4, a GST with high activity for both 4-HNE and
phospholipid hydroperoxides, and thus to address the apparent paradox
of an incongruent localization of an enzyme and its substrate(s). Our
results demonstrate that mGSTA4-4 is enriched at or near the plasma membrane of hepatocytes and transfected hepatoma cells, a
localization likely to facilitate its access to substrates and thus its
biological function. Furthermore, through site-directed mutagenesis
followed by transfection and in vitro binding experiments, we elucidated the mechanism by which mGSTA4-4 associates with membranes
and identified the amino acid residues (predominantly lysine 115)
responsible for the binding.
 |
EXPERIMENTAL PROCEDURES |
Plasmid Constructs and Transfection of Cells--
Vectors for
constitutive mammalian cell expression of the following proteins were
used in the course of the present work. (i) Wild-type mGSTA4-4: the
coding sequence of murine mGSTA4-4 (31, 32) was subcloned into the
mammalian expression vector pRC-CMV (Invitrogen) as described by this
group previously (33, 34), resulting in plasmid pRC-CMV/mGSTA4. (ii)
mGSTA4-4(K115E): the AAG codon encoding K115 in vector pRC-CMV/mGSTA4
was mutated to GAG using the QuikChange site-directed mutagenesis kit
(Stratagene, La Jolla, CA). (iii) Mitochondrially targeted mGSTA4-4:
DNA encoding the 24-amino acid mitochondrial targeting sequence of
human ornithine transcarbamoylase (Ref. 35; the clone was a generous
gift of Dr. Wayne A. Fenton, Yale University) was amplified by PCR
introducing the following two modifications. 1) To create a downstream
NdeI site needed for subsequent in-frame ligation, the last
codon of the leader signal was changed from AAT (Asn) to CAT (His). 2) To convert the suboptimal Kozak consensus sequence of the original ornithine transcarbamoylase clone to the canonical sequence GCC ACC
ATG G (initiator codon underlined; Ref. 36), which contains G in position +4, an additional codon (GCC encoding Ala) was inserted downstream of the initiator ATG. This increased the length of the
signal peptide to 25 amino acids but retained Leu (originally in
position 2, now in position 3 of the protein) which is part of the
amphiphilic structure of the targeting peptide. The resulting fragment
was ligated in frame to the 5'-end of a mGSTA4 cDNA
previously mutated to contain a NdeI site at the initiator
codon (31), and the entire coding sequence was subcloned into the
expression vector pcDNA3. The resulting
pcDNA3/mito(25aaOTC)-mGSTA4 construct was verified by sequencing.
HepG2 were transfected with the three expression vectors or with
control (insert-free) plasmid, and the resulting transfectants were
characterized biochemically as described previously (33, 34).
Bacterial Expression and Purification of GSTs for in Vitro
Studies--
The bacterial expression vector pET-9a/mGSTA4 was
described previously (31). The plasmid was subjected to site-directed mutagenesis to obtain the desired variants of codons 115 and/or 112. Wild-type mGSTA4-4 and its mutants (K115E, K115R, K115Q, K112C, and K112C/K115E) were then expressed in Escherichia
coli BL21(DE3)pLysS. Vector pET-11d/mGSTA1 (37) was a generous
gift of Dr. S. V. Singh, University of Pittsburgh. The
corresponding protein, mGSTA1-1, was expressed in E. coli
BL21(DE3). Human hGSTA4-4 was expressed in E. coli
BL21-CodonPlus(DE3)-RIL (Stratagene) from vector
pET-30a(+)/hGSTA4(silmut1-15) as described previously (38). All GSTs
were purified by glutathione affinity chromatography essentially
according to Ref. 39.
Enzyme Assays--
All bacterially expressed GSTs, including the
mutants of mGSTA4-4, were assayed for activity with a model substrate
(CDNB) and with the electrophilic lipid peroxidation product 4-HNE. GST activities were measured spectrophotometrically in a microtiter plate
reader (SPECTRAmax Plus, Molecular Devices, Sunnyvale, CA). Activity
with CDNB was measured at 25 °C according to Ref. 39. 4-HNE activity
was determined at 30 °C as described in Ref. 40.
Anti-GST Antibodies--
Polyclonal antibodies against
affinity-purified mGSTA4-4 and hGSTA4-4 were raised in chicken. The IgY
fraction (corresponding to mammalian IgG) was obtained from egg yolks
by polyethylene glycol precipitation (41). Control IgY was purified by
the same protocol from preimmune eggs. Anti-hGSTA1-1 (cross-reacting
with mGSTA1-1) was raised in rabbits as described previously (42), and
the IgG fraction was purified by protein A-Sepharose chromatography. Specificity of all antibodies was established by Western blotting using
authentic purified GSTs.
Immunolocalization of mGSTA4-4 in Transfected HepG2
Cells--
Confluent monolayers of HepG2 cells on glass coverslips
were rinsed with Dulbecco's PBS and fixed with 3% paraformaldehyde (Sigma) in PBS, pH 7.4, for 30 min. The permeabilization and blocking of nonspecific binding sites were performed in one step by incubating the monolayers with PBS containing 0.3% Triton X-100, 0.3% bovine serum albumin (Goldmark Biologicals, Phillipsburg, NJ), and 5% normal
goat serum (Jackson Immunoresearch, West Grove, PA) (buffer PBG) for 45 min. Monolayers were then incubated with anti-mGSTA4-4 chicken IgY
(1:100 in PBS supplemented with 0.2% bovine serum albumin) overnight
at room temperature, followed by extensive washing with PBS. For
control of nonspecific binding, preimmune chicken IgY at 1:100 dilution
was substituted for the anti-mGSTA4-4 antibody. Monolayers were
subsequently incubated with Alexa 488-conjugated goat anti-chicken IgG
(1:200 dilution; Molecular Probes, Eugene, OR) for 45 min, postfixed
with 3% paraformaldehyde, and mounted in 50% glycerol in PBS
containing 0.2% p-phenylenediamine as an anti-photobleaching agent. The monolayers were examined using an
Olympus IX70 fluorescent microscope equipped with DeltaVision PC
4.08 g deconvolution system (Applied Precision, Issaquah, WA). Images were reconstructed in XY and XZ planes using MetaMorph software
(version 3.5, Universal Images, West Chester, PA).
The mitochondrial localization of mGSTA4-4 fused to an ornithine
transcarbamoylase mitochondrial-targeting signal was confirmed by
co-localization studies with the mitochondria-specific fluorophore MitoTracker Orange (Molecular Probes, Eugene, OR). Stably transfected HepG2 cells cultured on glass coverslips were rinsed with PBS twice,
and incubated with standard culture medium containing 0.2 µM MitoTracker Orange for 15 min at 37 °C. The
monolayers were then rinsed twice with PBS and fixed and immunolabeled
for mGSTA4-4 as described above. Co-localization was examined using
Olympus IX 70 equipped with a DeltaVision deconvolution system. The
signal from Alexa 488-conjugated secondary antibody (for mGSTA4-4) was collected using 490/20 nm and 528/36 nm excitation/emission band pass
filters, and the signal from MitoTracker Orange was collected using the
555/28 nm and 617/73 nm band pass filter set. Neutral density filters
were applied to reduce the leak of the fluorescence signal in either
direction to undetectable levels.
Immunolocalization of mGSTA4-4 in Mouse
Hepatocytes--
Swiss-Webster mice were sacrificed by cervical
dislocation, and small cubes of liver were excised and immediately
placed in ice-cold fixative (3% paraformaldehyde in PBS, pH 7.4).
Following fixation for 4 h, tissue blocks were rinsed with PBS,
immersed in Optimum Cutting Temperature (OCT) compound
(Tissue-Tek, Sakura, Torrance, CA) overnight at 4 °C, cryopreserved
in liquid N2, and sectioned. The 5-µm cryosections were
immunolabeled for mGSTA4-4 using essentially the same approach as
described above for HepG2 cells with the exception that the
permeabilization/blocking step was performed for 2 h.
Binding of GSTs to Liposomes in Vitro--
Liposomes (small
unilamellar vesicles, SUV) from asolectin (crude soybean phospholipids;
Associated Concentrates, Woodside, NY, or Sigma, cat. no. P3644) were
prepared by swelling 50 mg of unpurified asolectin in 1 ml of water
under nitrogen for 1 h with intermittent shaking at room
temperature followed by exhaustive sonication in a cylindrical bath
sonicator (Laboratory Supplies, Hicksville, NY) under nitrogen. To
prepare liposomes of defined lipid composition, cholesterol (3 parts by
weight), phosphatidylcholine (from bovine brain, Sigma; 5 parts), and
phosphatidylethanolamine (from soybean, Sigma; 2 parts) with or without
acidic phospholipids (1 part) were dissolved in chloroform/methanol
(2:1). The following acidic phospholipids, all from Avanti Polar
Lipids, Alabaster, AL, were used: dioleoylphosphatidylglycerol,
phosphatidylserine (from brain), dioleoylphosphatidic acid,
phosphatidylinositol (from plant sources),
phosphatidylinositol-4,5-bisphosphate (from brain), and tetraoleoyl
cardiolipin. The solvent was removed under a stream of nitrogen, and
the lipids were hydrated and sonicated as described for asolectin.
Binding of GSTs to liposomes was measured by incubating 1 mg of
liposomes with 15 µg of protein for 30 min at room temperature in 0.5 ml of 100 mM KCl, 10 mM potassium phosphate, pH
7.4. Liposome-bound and free protein were separated by loading the
entire incubation mixture onto a 1 × 50-cm Sephadex G-200 superfine column equilibrated and eluted with the above buffer. Peaks
were pooled, evaporated to dryness in a Speedvac, and dissolved in 1 ml
of water, and the material was delipidated by precipitation with 10%
trichloroacetic acid followed by washing the pellet with ethanol and
ether. The samples were then subjected to SDS-PAGE, blotted to
nitrocellulose, and the blots were probed with antibodies against the
respective GST. Peroxidase-coupled secondary antibodies and the ECL
Plus kit (Amersham Biosciences) and fluorescence detection were used
for visualization and quantitation of bands on a Storm 860 imager
(Molecular Dynamics). Known amounts of bacterially expressed GSTs were
loaded on the same gel. The calibration curve constructed by
quantitation of bands resulting from the standards was used to
determine the amounts of liposome-associated and free GSTs, whose
loading amount was adjusted to be within the range of the calibration curve.
 |
RESULTS |
mGSTA4-4 Is Targeted to the Plasma Membrane in Mouse Hepatocytes
and in Transfected HepG2 Cells--
Immunostaining of frozen sections
of mouse liver with an anti-mGSTA4-4 antibody revealed a localization
of the enzyme predominantly at the plasma membrane of the hepatocytes
(Fig. 1A). Some labeling was
also present within discrete areas of the cytoplasm, but no significant
diffuse cytoplasmic labeling was observed in any of the examined
preparations. Interestingly, the plasma membrane was labeled to a
similar degree regardless of the membrane domain, i.e.
apical (canalicular) versus basolateral. No significant
labeling was observed in liver sections incubated with preimmune
chicken IgY (Fig. 1B).

View larger version (83K):
[in this window]
[in a new window]
|
Fig. 1.
Immunolocalization of endogenous mGSTA4-4 in
mouse hepatocytes. Cryosections (5 µm) of mouse liver were
immunostained with anti-mGSTA4-4 chicken IgY and Alexa 488-conjugated
secondary antibody. Panel A shows an optical section of
~0.4 µm-thickness obtained by a deconvolution algorithm. Note the
plasma membrane labeling at the basolateral membrane domains
(arrows) as well as at the apical (canalicular) membrane
domains (arrowhead). Discrete areas of labeling within the
cytoplasm are indicated by asterisks. Panel B
shows a section incubated with the preimmune chicken IgY. The
bar represents 5 µm.
|
|
The microscopic analysis of the mGSTA4-4-transfected HepG2 cells
revealed that ~40% of all cells exhibited a strong and specific fluorescent signal from mGSTA4-4. The majority of mGSTA4-4 was localized to the plasma membrane and, to a lesser degree, to the narrow
zone of adjacent cytoplasm (Fig.
2A). Analysis of images reconstructed in the XZ plane (Fig. 2B) confirmed the
above-mentioned localization of mGSTA4-4 in transfected HepG2 cells.
The specificity of the immunostaining was demonstrated by the absence
of fluorescent signal in monolayers in which the anti-mGSTA4-4 antibody
was replaced with preimmune chicken IgY (Fig. 2C).

View larger version (105K):
[in this window]
[in a new window]
|
Fig. 2.
Immunolocalization of mGSTA4-4 in HepG2 cells
transfected with wild-type mGSTA4 cDNA.
Cultured stably transfected HepG2 cells were fixed at 80-90%
confluency and immunolabeled using anti-mGSTA4-4 chicken IgY. Note that
the immunolabeling is present predominantly at the plasma membrane and
within a narrow zone of adjacent cytoplasm. This pattern is well
visible in images obtained in both the XY (Panel A) and the
XZ (Panel B) planes. Also, note the absence of a fluorescent
signal in cells incubated with preimmune chicken IgY (Panel
C). The line in Panel A indicates the XZ
plane of reconstruction shown in Panel B. The broken
line in Panel B indicates culture support. The
bar represents 5 µm.
|
|
Further confirmation of the specificity of immunolabeling was obtained
from cells expressing mGSTA4-4 fused to a mitochondrial-targeting peptide. As expected, in these cells the majority of mGSTA4-4 was
localized to discrete intracytoplasmic structures relatively homogeneously distributed within the perinuclear cytoplasm (Fig. 3A). The fluorescent signal
from the majority of these particles co-localized with mitochondria
labeled with MitoTracker Orange (Fig. 3, B and
C). Importantly, neither labeling of the plasma membrane nor
diffuse cytoplasmic staining was observed in these cells, which
confirmed the high specificity of the anti-GST antibody used in these
studies. Some cells expressed very little of the transfected mGSTA4-4.
In these cells, no immunolabeling with mGSTA4-4 antibody was detected,
whereas the typical mitochondrial staining pattern was still observed
(Fig. 3C, asterisks).

View larger version (50K):
[in this window]
[in a new window]
|
Fig. 3.
Immunolocalization of mGSTA4-4 in HepG2 cells
transfected with mGSTA4 cDNA fused to a
mitochondrial-targeting sequence. Cells were incubated with
MitoTracker Orange, fixed, and immunolabeled for mGSTA4-4 as described
under "Experimental Procedures." Note that most areas
positive for mGSTA4-4 (Panel A) co-localize with
mitochondria labeled with MitoTracker (Panel B). Panel
C is an overlay showing co-localization of both fluorescent
signals (arrows; orange to yellow).
Asterisks mark cells with no significant mGSTA4-4
labeling.
|
|
In contrast to the transfected cells described above, no detectable
immunostaining was observed in control HepG2 cells transfected with
insert-free vector (data not shown).
Intracellular Localization of mGSTA4-4(K115E)--
The
intracellular distribution of the mGSTA4-4(K115E) mutant was
distinctively different from that observed in HepG2 cells expressing
the wild-type protein. The mutated protein was diffusely distributed
within the cytoplasm, and no preferential targeting to intracellular
organelles or plasma membrane was observed (Fig. 4). This diffuse cytoplasmic distribution
was observed in the XY as well as in the XZ planes of the HepG2 cells
(Fig. 4, A and B, respectively). This observation
suggested that lysine 115 is critically important for the plasma
membrane targeting of the protein.

View larger version (102K):
[in this window]
[in a new window]
|
Fig. 4.
Immunolocalization of mGSTA4-4(K115E) mutant
protein expressed in HepG2 cells. Cells were fixed at 80-90%
confluency and immunolabeled using anti-mGSTA4-4 chicken IgY. The
immunolabeling is diffusely distributed throughout the cytoplasm, which
is well visible in both XY and XZ planes (Panels A and
B, respectively). No plasma membrane staining could be seen.
Note the absence of a fluorescent signal in cells incubated with
preimmune chicken IgY (Panel C). The line in
Panel A indicates the XZ plane of reconstruction shown in
Panel B. The broken line in Panel B
indicates culture support. The bar represents 5 µm.
|
|
Binding of mGSTA4-4 to Asolectin Liposomes in Vitro--
In
agreement with the membrane association of mGSTA4-4 observed
microscopically in intact cells, the enzyme had the ability to bind to
phospholipid (asolectin) liposomes (Fig.
5). Under the conditions used,
approximately half of mGSTA4-4 associated with the vesicles. Although
true binding constants were not measured, the ratio of bound to free
protein (used as the binding parameter in Fig. 5) constitutes an
apparent binding constant. This is justified because the vesicle
surface is in large excess compared with the protein. Thus, the
concentration of free liposomal binding sites will remain constant for
all GSTs tested, and can be subsumed into the apparent (composite)
binding constant. The conclusion that liposomal binding surface in
excess over GST protein was reached as follows. Under the experimental
conditions used, the protein concentration was 0.6 µM,
and the approximate concentration of liposomes was 0.4-0.5
µM (as determined from an average radius of SUVs of 14.9 nm (43), a membrane thickness of 3 nm, and an average surface
requirement of 0.71 nm2 per phospholipid molecule (44), or
from the experimentally obtained internal volume of SUVs of ~1
µl/mg lipid). Given that the cross-section of a mGSTA4-4 molecule is
less than 40 nm2 (on the basis of crystal structures; Refs.
45, 46) and the surface of a SUV is ~3000 nm2, less than
2% of the total surface of liposomes is occupied by protein. It should
also be noted that the dissociation of mGSTA4-4 from its complex with
liposomes is slow because discrete peaks of bound and free protein (as
opposed to a smear) are obtained on Sephadex gel filtration, which
requires several hours to complete.

View larger version (26K):
[in this window]
[in a new window]
|
Fig. 5.
Binding of mGSTA4-4, its mutants, and
unrelated GSTs to asolectin liposomes. Fifteen micrograms of the
respective protein were incubated with 1 mg of sonicated liposomes
composed of asolectin. Binding to liposomes was evaluated as described
under "Experimental Procedures." Results are presented as the ratio
of vesicle-bound to free protein.
|
|
Binding of mGSTA4-4 Mutants and of Other GSTs to Asolectin
Liposomes in Vitro--
Loss of plasma membrane association of the
mGSTA4-4(K115E) mutant in transfected cells suggested that lysine 115 may play a role in the mechanism involved in the targeting and/or
binding of the enzyme to the plasma membrane. To verify this hypothesis we examined the binding of mGSTA4-4(K115E) to liposomes in
vitro. As shown in Fig. 5, membrane association of the mutant
enzyme was significantly reduced as compared with the wild-type
protein. In contrast, binding was preserved in mGSTA4-4(K115R) and was intermediate in mGSTA4-4(K115Q), indicating that a positive charge on
the amino acid side chain in position 115 favors binding, whereas a
negative charge counteracts binding. The effect was position-specific because the elimination of a positive charge in position 112 in the
mGSTA4-4(K112C) mutant did not affect binding.
Membrane association was essentially abolished in the
mGSTA4-4(K115E+K112C) double mutant, indicating that the
binding is largely due to interactions of the membrane with specific
amino acids in the 110-120 region, and that little or no binding
is caused by other parts of the molecule or by random, nonspecific interactions. Interestingly, mGSTA1-1 and hGSTA4-4, enzymes
that contain a negatively charged amino acid in position 115 (Fig. 6), exhibited liposome association
that was moderate but higher than that of the mGSTA4-4 mutant
carrying a negative charge on the side chain in position 115 (Fig.
5).

View larger version (25K):
[in this window]
[in a new window]
|
Fig. 6.
Partial sequence alignment of GSTs under
study. Amino acid residues 110-120 of mGSTA4-4, its mutants, and
of mGSTA1-1 and hGSTA4-4 are shown. This region joins helices 4
and 5 of each subunit and forms the ridge that defines the cleft
between subunits that provides access to the active sites. Residue 115, found in the course of the present work to be important in the membrane
association of mGSTA4-4, is boxed.
|
|
mGSTA4-4 Mutants Are Enzymatically Active--
To rule out the
possibility that the loss of membrane association of certain mGSTA4-4
mutants is due to a gross change of conformation and/or loss of protein
stability, the catalytic activity of all enzymes was determined. As
shown in Table I, all enzymes were fully
active with the model substrate CDNB as well as with the lipid
peroxidation end product 4-HNE (with the exception of mGSTA1-1, which
is known to have low activity for 4-HNE). Thus, the proteins fold
normally upon bacterial expression and are able to retain a native
conformation, indicating that the effects of mutations of residues 115 and/or 112 are local rather than global.
View this table:
[in this window]
[in a new window]
|
Table I
Specific activity of bacterially expressed GSTs used in the present
study, measured with 4-HNE and CDNB as substrates
Specific activity was measured as described in "Experimental
Procedures" and is listed as mean ± S.D. (n = 3).
|
|
Binding of mGSTA4-4 to Liposomes of Defined Lipid
Composition--
Asolectin is a crude mixture of lipids that may
contain residual proteins. To ascertain that membrane association of
mGSTA4-4 does not require additional proteins, binding assays were
carried out with liposomes made from chromatographically purified
lipids. A lipid composition was chosen that mimics that of the plasma membrane. As shown in Fig. 7, mGSTA4-4
was able to bind to liposomes composed of phosphatidylcholine,
phosphatidylethanolamine, and cholesterol, although not as well as to
asolectin liposomes. The inner leaflet of the plasma membrane is
enriched in acidic phospholipids, particularly phosphatidylserine and
phosphatidylinositol (47, 48). The incorporation of acidic
phospholipids into liposomes increased the binding of mGSTA4-4 to the
level seen with asolectin. Although the effects of the individual
lipids differed somewhat from each other, all tested acidic lipids
supported increased binding of mGSTA4-4 to liposomes. The
mGSTA4-4(K115E) mutant associated poorly with either defined or
asolectin liposomes, and in vesicles of defined lipid composition that
residual binding was not dependent on the presence of acidic
phospholipids.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 7.
Binding of wild-type mGSTA4-4 and of
mGSTA4-4(K115E) to liposomes of defined lipid composition.
Vesicles were prepared either from phosphatidylcholine
(PC)/phosphatidylethanolamine
(PE)/cholesterol (5:2:3 by weight), or from
PC/PE/cholesterol/L (5:2:3:1 by
weight), where L stands for the acidic phospholipid
indicated in the figure. PG, phosphatidylglycerol;
PS, phosphatidylserine; PA, phosphatidic acid;
PI, phosphatidylinositol; PIP2,
phosphatidylinositol-4,5-bisphosphate; CL, cardiolipin.
Binding assays were carried out as described under "Experimental
Procedures" and in the legend to Fig. 5. Association with asolectin
liposomes (from Fig. 5) is shown for comparison. Closed
bars, mGSTA4-4; open bars, mGSTA4-4(K115E).
|
|
 |
DISCUSSION |
Among canonical GSTs, mGSTA4-4 and its orthologs in other species
are distinguished by their high catalytic efficiency for glutathione
conjugation of 4-hydroxyalkenals (14, 40). At elevated concentrations
the latter are highly toxic electrophiles (49), whereas at
physiological levels they appear to serve as messenger molecules
(reviewed in Refs. 7, 50). Because 4-hydroxyalkenals are derived from
membrane-bound phospholipid hydroperoxides (51) but are diffusible,
they would be most efficiently metabolized by enzymes located at or
near the site of their formation, i.e. the membrane. Such
localization would also augment the glutathione peroxidase activity of
GSTs toward phospholipid hydroperoxides. Contrary to older reports
(52), there is now ample evidence that GSTs, including
mGSTA4-4, can act directly on phospholipid hydroperoxides
without the need for prior release of the oxidized fatty acid by a
phospholipase (9, 10). Because phospholipid hydroperoxides are likely
to be associated with membranes, their metabolism would be facilitated
by a membrane localization of the GST.
The pattern of distribution of immunofluorescence in mouse liver
sections indicates that mGSTA4-4 is indeed enriched at or near the
plasma membrane of normal mouse hepatocytes (Fig. 1). We extended this
initial observation, and determined the mechanism governing the
localization by two distinct but complementary approaches: transfection
of cultured cells, and direct in vitro binding experiments.
HepG2 cells do not express endogenous enzymes cross-reacting with
anti-mGSTA4-4 antibodies or exhibiting 4-HNE conjugating activity (33),
and they were therefore chosen for transfection studies. Fluorescent
microscopy on stable HepG2 transfectants expressing mGSTA4-4 clearly
demonstrated a localization of the enzyme to the plasma membrane and/or
a narrow adjacent zone of the cytosol. Image reconstruction in the XZ
plane shows that staining that could be interpreted as diffuse or
cytosolic in standard epifluorescent whole-cell images is actually
because of enzyme associated with plasma membranes oriented parallel to
the culture substratum. These observations confirmed our original
hypothesis that the transfected HepG2 cell model closely resembles
normal mouse hepatocytes with respect to the intracellular targeting of
mGSTA4-4.
The plasma membrane association of mGSTA4-4 was lost when the protein
was fused to a mitochondrial import signal peptide that targets it to
the mitochondrial matrix. Technically, the observed shift of the
intracellular distribution of the fluorescence validates the overall
methodology used in these studies and, in particular, the specificity
of the antibody. Conceptually, the result indicates that the plasma
membrane association of wild-type mGSTA4-4 is of relatively
low-affinity as it cannot effectively compete with the mitochondrial
protein import machinery. It should be noted that mitochondrial
localization has been reported for the human hGSTA4-4 (28), a GST whose
function but not sequence is similar to that of mGSTA4-4
(38). Interestingly, at least a partial localization to the
mitochondrial matrix has also been described for rGSTA4-4 (27), the rat
ortholog of mGSTA4-4. Our present results do not indicate a
mitochondrial localization of native mGSTA4-4; such localization was
observed only for an engineered protein that contained a heterologous
mitochondrial-targeting peptide. The difference in localization could
be because of the species (rat versus mouse) or perhaps to a
modification of the rat enzyme leading to an alternative form with an
increased molecular weight in the rat (27) but not in the mouse.
Tissue-purified (53) or bacterially expressed (31) mGSTA4-4 is soluble
in aqueous buffers, in which it resembles other canonical GSTs. The
structural basis of the ability of mGSTA4-4 to act as a peripheral
membrane protein is thus of obvious mechanistic interest. Inspection of
the recently available crystal structure of the enzyme (46) revealed
the presence of a positively charged residue, lysine 115, located in
each subunit of the dimeric enzyme in the surface loop connecting helices 4 and 5 and thus highly exposed to solvent. The lysine
115 residues of both subunits flank the intersubunit cleft that harbors
the active sites of the enzyme (Fig. 8).
In contrast, the predominant Alpha-class GSTs, which are devoid of
4-HNE-conjugating activity, e.g. mGSTA1-1 or human hGSTA1-1,
contain a negatively charged residue (aspartic or glutamic acid,
respectively) in position 115. This raised the possibility that the
lysine 115 "fingers" of mGSTA4-4 interact with negative charges on
the surface of membranes. To test this hypothesis, we mutated lysine
115 of mGSTA4-4 to glutamic acid. The mutation did not affect the
catalytic properties of the enzyme (Table I), but caused a dramatic
shift of its intracellular localization from the plasma membrane to a
diffuse cytosolic distribution (compare Figs. 2 and 4).

View larger version (65K):
[in this window]
[in a new window]
|
Fig. 8.
Model of membrane association of
mGSTA4-4. The crystal structure of mGSTA4-4 (46) was docked to a
model (in scale) of a phospholipid bilayer in an orientation allowing
electrostatic interaction of lysine 115 side chains with negatively
charged phosphates or phosphatidylserine head groups on the surface of
the membrane. The possible channeling of membrane-derived substrates
such as 4-HNE to the active sites of the enzyme under exclusion of the
bulk solution is schematically depicted by arrows.
|
|
The key role of lysine 115 in membrane association of
mGSTA4-4 could be confirmed by in vitro binding
experiments to liposomes. The ability of wild-type mGSTA4-4 to bind to
lipid vesicles was largely abrogated by the K115E mutation. The
requirement is for a positive charge rather than for the specific
structure of lysine because arginine could substitute for lysine 115 without a loss of membrane association. A mutant with an uncharged
amino acid in position 115 had intermediate binding properties. On the
membrane side the binding is in part dependent on the presence of
acidic phospholipids. Unlike certain cytoskeletal proteins that bind specific lipids, particularly phosphatidylinositol phosphates, via
complex binding sites involving multiple amino acids (reviewed in Ref.
48), mGSTA4-4 appears to interact with any acidic phospholipid. This
may explain the association of mGSTA4-4 with the plasma membrane but
not, or to a lesser degree, with intracellular membranes (Figs. 1 and
2). Approximately 20% of plasma membrane lipids carry a net negative
charge, and the majority of these lipids (80-100%) are localized in
the cytoplasmic leaflet of the membrane (47, 54). In contrast, with the
exception of the inner mitochondrial membrane, which is normally
inaccessible to the cytosolic mGSTA4-4, the percentage of acidic lipids
in intracellular membranes is lower than in the plasma membrane.
Moreover, in membranes such as the endoplasmic reticulum the
distribution of lipids between membrane leaflets is thought to be
essentially symmetrical (55), further decreasing the effective membrane
surface charge available to cytosolic proteins. Although it is
currently unknown whether mGSTA4-4 binding to the plasma
membrane is modulated by structures such as lipid rafts (56), data on
lipid composition and asymmetry clearly indicate that the plasma
membrane should be the primary target for such binding. Diffuse
staining in a zone immediately adjacent to the plasma membrane (Fig. 2)
could be because of endocytic vesicles that, until they fuse with
intracellular structures, retain the lipid composition of the plasma membrane.
In addition to pinpointing the amino acid residue in mGSTA4-4
that is involved in membrane binding, the in vitro
experiments have also demonstrated that the membrane association can
occur in a simple, well-defined system consisting of pure mGSTA4-4 and liposomes of defined composition. Thus, the binding is not mediated by,
nor does it require, additional proteins, at least in the system studied.
Unexpectedly, two GSTs with a negative charge in position 115 had the
ability to associate with liposomes, albeit relatively poorly. These
were mGSTA1-1, by analogy with human hGSTA1-1 likely to play
an important role in the metabolism of phospholipid hydroperoxides (10), and hGSTA4-4, one of two human enzymes with high
4-HNE-conjugating activity (38). It should be noted, however, that
mGSTA4-4 and hGSTA4-4 are only 59% identical/73% similar on the
protein level and probably acquired similar catalytic properties by
convergent evolution rather than a common ancestor. Binding of a GST to
membranes despite a negative charge in position 115 prompted us to
examine the possible involvement of other residues. If the geometry of binding is similar to the model shown in Fig. 8 as indicated by the
results of Lys-115 mutagenesis, only a limited set of residues could be
close enough to the membrane to contribute significantly to binding. We
considered residue 115, located at the tip of the loop connecting helices 4 and 5, and five additional residues on either side. For each
charged amino acid in this region, the electrostatic interaction with
the membrane (attraction or repulsion) was estimated taking into
account its distance from the membrane. The sum of these interactions
correlated very well with the membrane association (Fig.
9A). The predictive power of
the model is illustrated by the fact that points representing mGSTA1-1
and hGSTA4-4, which were not used in the regression, were nevertheless
close to the regression line established for mGSTA4-4 and its mutants
(Fig. 9A). This suggests that all of the GSTs under study
bind to membranes by a similar mechanism. The analysis was then
repeated disregarding the contribution of residues other than 115 (Fig.
9B). Comparison of the results indicates that taking into
account the charges in the entire 110-120 region improves the
predictive power of the model, but only marginally; a 25% decrease of
the sum of squared residuals, a measure of how well the model
represents the experimental data, for mGSTA1-1 and hGSTA4-4. Thus,
consideration of additional, nearby residues refines the model and may
explain the moderate membrane association of some GSTs but also
confirms the key role of residue 115.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 9.
Relationship between binding of GSTs to
liposomes and the presence of charged amino acids in positions
110-120. Panel A, the ratio of liposome bound to free GST
for mGSTA4-4 and its mutants ( ; in order of increasing ordinate
value: mGSTA4-4(K112C/K115E), mGSTA4-4(K115E), mGSTA4-4(K115Q),
mGSTA4-4, mGSTA4-4(K112C), and mGSTA4-4(K115R)), for mGSTA1-1 ( ),
and for hGSTA4-4 ( ), was plotted against the effective electrostatic
interaction of amino acids 110-120 with negative charges on a
hypothetical membrane positioned as shown in Fig. 8. The interaction
was calculated by measuring on the model of Fig. 8 the shortest
distance between each of the above 11 amino acids and the plane of the
membrane. The distance between the -amino group of K115 and the
plane of the membrane was assumed to be 3 Å, which is typical for an
ion pair. Electrostatic interactions of individual amino acids with the
membrane (negative if the amino acid carries a negative charge,
positive for positively charged amino acids, and zero for neutral amino
acids) were weighted by the reciprocal square of their relative
distance from the membrane (calculated as its distance from the
membrane in Å divided by 3 Å). The sum of the weighted interactions
for amino acids 110-120 is shown for each protein on the
abscissa. The exponential function y = a exp(bx) was
fitted to the data points representing mGSTA4-4 and its mutants
(excluding mGSTA1-1 and hGSTA4-4, which differ in residues other than
the mutated amino acids in the 110-120 region). An exponential
function was chosen because the ratio of bound to free protein
represents an apparent binding constant that is related to the free
energy of binding (of which electrostatic interactions are a component)
by the general equation G = RTlnK. As
expected, the exponential function gave a better fit than linear
regression. The sum of squared residuals (SSR) relative to
the exponential regression line was calculated for mGSTA1-1 and
hGSTA4-4. Panel B, the same model as in Panel A
was assumed except that only the amino acid in position 115 was taken
into account in calculating the effective electrostatic interaction of
the proteins with the membrane.
|
|
Our results support the idea that proteins considered to be cytosolic
are not necessarily uniformly distributed within the cell. Rather,
these proteins may assume an intracellular localization that is
appropriate for their function. Such localization may be transient and
can be mediated by weak interactions and thus would not be apparent in
biochemical cell fractionation studies. The association of mGSTA4-4
with the plasma membrane could serve as an example. Such localization
may facilitate the metabolism of substrates generated within or bound
to membranes and might increase the biological effectiveness of the
enzyme beyond that predicted from its classical kinetic parameters.
 |
ACKNOWLEDGEMENTS |
We thank Dr. Wayne A. Fenton, Yale
University, for the cDNA encoding human ornithine
transcarbamoylase, and Dr. Slawomir Pikula, Department of Cellular
Biochemistry, Nencki Institute of Experimental Biology, Warsaw,
Poland, for helpful discussions.
 |
FOOTNOTES |
*
This work was supported in part by National Institutes of
Health Grants K08-DK02557 (to A. J.), CA77495 (to S. A.), CA27967 and
EY04396 (to Y. C. A), and ES07804 (to P. Z.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
Present address: Dept. of Pharmacology, University of
Pittsburgh, Pittsburgh, PA 15267.
§§
To whom correspondence should be addressed: Central Arkansas
Veterans Healthcare System Medical Research (151/LR), 4300 West 7th
St., Little Rock, AR 72205. Tel.: 501-257-4843; Fax: 501-257-4822; E-mail: zimniakpiotr@uams.edu.
Published, JBC Papers in Press, November 19, 2001, DOI 10.1074/jbc.M109678200
 |
ABBREVIATIONS |
The abbreviations used are:
4-HNE, 4-hydroxynonenal;
GST, glutathione S-transferase;
CDNB, 1-chloro-2,4-dinitrobenzene;
SSR, sum of squared
residuals;
SUV, small unilamellar vesicle (liposome);
PBS, phosphate-buffered saline.
 |
REFERENCES |
| 1.
|
Brigelius-Flohe, R.
(1999)
Free Radic. Biol. Med.
27,
951-965
|
| 2.
|
Esterbauer, H.
(1993)
Am. J. Clin. Nutr.
57,
779S-86S
|
| 3.
|
Schneider, C.,
Tallman, K. A.,
Porter, N. A.,
and Brash, A. R.
(2001)
J. Biol. Chem.
276,
20831-20838
|
| 4.
|
Uchida, K.,
Szweda, L. I.,
Chae, H.-Z.,
and Stadtman, E. R.
(1993)
Proc. Natl. Acad. Sci. U. S. A.
90,
8742-8746
|
| 5.
|
Cohn, J. A.,
Tsai, L.,
Friguet, B.,
and Szweda, L. I.
(1996)
Arch. Biochem. Biophys.
328,
158-164
|
| 6.
|
Yan, L. J.,
and Sohal, R. S.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
12896-12901
|
| 7.
|
Dianzani, M. U.,
Barrera, G.,
and Parola, M.
(1999)
Acta Biochim. Pol.
46,
61-75
|
| 8.
|
Singhal, S. S.,
Saxena, M.,
Ahmad, H.,
Awasthi, S.,
Haque, A. K.,
and Awasthi, Y. C.
(1992)
Arch. Biochem. Biophys.
299,
232-241
|
| 9.
|
Hurst, R.,
Bao, Y.,
Jemth, P.,
Mannervik, B.,
and Williamson, G.
(1998)
Biochem. J.
332,
97-100
|
| 10.
|
Zhao, T.,
Singhal, S. S.,
Piper, J. T.,
Cheng, J.,
Pandya, U.,
Clark-Wronski, J.,
Awasthi, S.,
and Awasthi, Y. C.
(1999)
Arch. Biochem. Biophys.
367,
216-224
|
| 11.
|
Yang, Y.,
Cheng, J. Z.,
Singhal, S. S.,
Saini, M.,
Pandya, U.,
Awasthi, S.,
and Awasthi, Y. C.
(2001)
J. Biol. Chem.
276,
19220-19230
|
| 12.
|
Ursini, F.,
Maiorino, M.,
Valente, M.,
Ferri, L.,
and Gregolin, C.
(1982)
Biochim. Biophys. Acta
710,
197-211
|
| 13.
|
Maiorino, M.,
Roveri, A.,
Gregolin, C.,
and Ursini, F.
(1986)
Arch. Biochem. Biophys.
251,
600-605
|
| 14.
|
Awasthi, Y. C.,
Zimniak, P.,
Awasthi, S.,
Singhal, S. S.,
Srivastava, S. K.,
Piper, J. T.,
Chaubey, M.,
Petersen, D. R., He, N.-G,
Sharma, R.,
Singh, S. V.,
Khan, M. F.,
Ansari, G. A. S.,
and Boor, P. J.
(1996)
in
Glutathione S-transferases: Structure, Function and Clinical Implications
(Vermeulen, N. P. E.
, Mulder, G. J.
, Nieuwenhuyse, H.
, Peters, W. H. M.
, and van Bladeren, P. J., eds)
, pp. 111-124, Taylor & Francis, London
|
| 15.
|
Cheng, J.-Z.,
Sharma, R.,
Yang, Y.,
Singhal, S. S.,
Sharma, A.,
Saini, M. K.,
Singh, S. V.,
Zimniak, P.,
Awasthi, S.,
and Awasthi, Y. C.
(2001)
J. Biol. Chem.
276,
41213-41223
|
| 16.
|
Mannervik, B.,
and Danielson, U. H.
(1988)
CRC Crit. Rev. Biochem.
23,
283-337
|
| 17.
|
Hayes, J. D.,
and Pulford, D. J.
(1995)
Crit. Rev. Biochem. Mol. Biol.
30,
445-600
|
| 18.
|
Salinas, A. E.,
and Wong, M. G.
(1999)
Curr. Med. Chem.
6,
279-309
|
| 19.
|
Armstrong, R. N.
(1997)
Chem. Res. Toxicol.
10,
2-18
|
| 20.
|
Armstrong, R. N.
(1998)
Curr. Opin. Chem. Biol.
2,
618-623
|
| 21.
|
Vuilleumier, S.
(1997)
J. Bacteriol.
179,
1431-1441
|
| 22.
|
Sundberg, A. G.,
Nilsson, R.,
Appelkvist, E. L.,
and Dallner, G.
(1993)
Pharmacol. Toxicol.
72,
321-331
|
| 23.
|
Aiso, S.,
Yasuda, K.,
Shiozawa, M.,
Yamamoto, H.,
and Sogo, T.
(1989)
J. Histochem. Cytochem.
37,
1247-1252
|
| 24.
|
Ali-Osman, F.,
Brunner, J. M.,
Kutluk, T. M.,
and Hess, K.
(1997)
Clin. Cancer Res.
3,
2253-2261
|
| 25.
|
van Lieshout, E. M.,
van Haelst, U. J.,
Wobbes, T.,
and Peters, W. H.
(1999)
Jpn. J. Cancer Res.
90,
530-535
|
| 26.
|
Forkert, P.-G.,
D'Costa, D.,
and El-Mestrah, M.
(1999)
Am. J. Respir. Cell Mol. Biol.
20,
143-152
|
| 27.
|
Bhagwat, S. V.,
Vijayasarathy, C.,
Raza, H.,
Mullick, J.,
and Avadhani, N. G.
(1998)
Biochem. Pharmacol.
56,
831-839
|
| 28.
|
Gardner, J. L.,
and Gallagher, E. P.
(2001)
Arch. Biochem. Biophys.
390,
19-27
|
| 29.
|
Jensson, H.,
Guthenberg, C.,
Alin, P.,
and Mannervik, B.
(1986)
FEBS Lett.
203,
207-209
|
| 30.
|
Hubatsch, I.,
Ridderstrom, M.,
and Mannervik, B.
(1998)
Biochem. J.
330,
175-179
|
| 31.
|
Zimniak, P.,
Singhal, S. S.,
Srivastava, S. K.,
Awasthi, S.,
Sharma, R.,
Hayden, J. B.,
and Awasthi, Y. C.
(1994)
J. Biol. Chem.
269,
992-1000
|
| 32.
|
Zimniak, P.,
Eckles, M. A.,
Saxena, M.,
and Awasthi, Y. C.
(1992)
FEBS Lett.
313,
173-176
|
| 33.
|
Zimniak, L.,
Awasthi, S.,
Srivastava, S. K.,
and Zimniak, P.
(1997)
Toxicol. Appl. Pharmacol.
143,
221-229
|
| 34.
|
He, N. G.,
Singhal, S. S.,
Srivastava, S. K.,
Zimniak, P.,
Awasthi, Y. C.,
and Awasthi, S.
(1996)
Arch. Biochem. Biophys.
333,
214-220
|
| 35.
|
Horwich, A. L.,
Fenton, W. A.,
Williams, K. R.,
Kalousek, F.,
Kraus, J. P.,
Doolittle, R. F.,
Konigsberg, W.,
and Rosenberg, L. E.
(1984)
Science
224,
1068-1074
|
| 36.
|
Kozak, M.
(1992)
Annu. Rev. Cell Biol.
8,
197-225
|
| 37.
|
Xia, H.,
Pan, S. S., Hu, X.,
Srivastava, S. K.,
Pal, A.,
and Singh, S. V.
(1998)
Arch. Biochem. Biophys.
353,
337-348
|
| 38.
|
Cheng, J. Z.,
Yang, Y.,
Singh, S. P.,
Singhal, S. S.,
Awasthi, S.,
Pan, S. S.,
Singh, S. V.,
Zimniak, P.,
and Awasthi, Y. C.
(2001)
Biochem. Biophys. Res. Commun.
282,
1268-1274
|
| 39.
|
Habig, W. H.,
Pabst, M. J.,
and Jakoby, W. B.
(1974)
J. Biol. Chem.
249,
7130-7139
|
| 40.
|
Alin, P.,
Danielson, U. H.,
and Mannervik, B.
(1985)
FEBS Lett.
179,
267-270
|
| 41.
|
Polson, A.
(1990)
Immunol. Invest.
19,
253-258
|
| 42.
|
Ahmad, H.,
Singh, S. V.,
Medh, R. D.,
Ansari, G. A. S.,
Kurosky, A.,
and Awasthi, Y. C.
(1988)
Arch. Biochem. Biophys.
266,
416-426
|
| 43.
|
Matsuzaki, K.,
Murase, O.,
Sugishita, K.,
Yoneyama, S.,
Akada, K.,
Ueha, M.,
Nakamura, A.,
and Kobayashi, S.
(2000)
Biochim. Biophys. Acta
1467,
219-226
|
| 44.
|
Engelman, D. M.
(1969)
Nature
223,
1279-1280
|
| 45.
|
Krengel, U.,
Schroter, K. H.,
Hoier, H.,
Arkema, A.,
Kalk, K. H.,
Zimniak, P.,
and Dijkstra, B. W.
(1998)
FEBS Lett.
422,
285-290
|
| 46.
|
Xiao, B.,
Singh, S. P.,
Nanduri, B.,
Awasthi, Y. C.,
Zimniak, P.,
and Ji, X.
(1999)
Biochemistry
38,
11887-11894
|
| 47.
|
Zachowski, A.
(1993)
Biochem. J.
294,
1-14
|
| 48.
|
Niggli, V.
(2001)
Trends Biochem. Sci.
26,
604-611
|
| 49.
|
Eckl, P. M.,
Ortner, A.,
and Esterbauer, H.
(1993)
Mut. Res.
290,
183-192
|
| 50.
|
Dianzani, M. U.
(1998)
Free Radic. Res.
28,
553-560
|
| 51.
|
Esterbauer, H.,
Schaur, R. J.,
and Zollner, H.
(1991)
Free Radic. Biol. Med.
11,
81-128
|
| 52.
|
Tan, K. H.,
Meyer, D. J.,
Belin, J.,
and Ketterer, B.
(1984)
Biochem. J.
220,
243-252
|
| 53.
|
Medh, R. D.,
Saxena, M.,
Singhal, S. S.,
Ahmad, H.,
and Awasthi, Y. C.
(1991)
Biochem. J.
278,
793-799
|
| 54.
|
Yeagle, P.
(1992)
The Structure of Biological Membranes
, CRC Press, Boca Raton
|
| 55.
|
Sprong, H.,
van der Sluijs, P.,
and van Meer, G.
(2001)
Nat. Rev. Mol. Cell. Biol.
2,
504-513
|
| 56.
|
Simons, K.,
and Toomre, D.
(2000)
Nat. Rev. Mol. Cell. Biol.
1,
31-39
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
L. Stella, V. Pallottini, S. Moreno, S. Leoni, F. De Maria, P. Turella, G. Federici, R. Fabrini, K. F. Dawood, M. L. Bello, et al.
Electrostatic Association of Glutathione Transferase to the Nuclear Membrane: EVIDENCE OF AN ENZYME DEFENSE BARRIER AT THE NUCLEAR ENVELOPE
J. Biol. Chem.,
March 2, 2007;
282(9):
6372 - 6379.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Leslie, A. Haimeur, and M. P. Waalkes
Arsenic Transport by the Human Multidrug Resistance Protein 1 (MRP1/ABCC1): EVIDENCE THAT A TRI-GLUTATHIONE CONJUGATE IS REQUIRED
J. Biol. Chem.,
July 30, 2004;
279(31):
32700 - 32708.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.-A. Robin, S. K. Prabu, H. Raza, H. K. Anandatheerthavarada, and N. G. Avadhani
Phosphorylation Enhances Mitochondrial Targeting of GSTA4-4 through Increased Affinity for Binding to Cytoplasmic Hsp70
J. Biol. Chem.,
May 23, 2003;
278(21):
18960 - 18970.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Rinaldi, E. Eliasson, S. Swedmark, and R. Morgenstern
Reactive Intermediates and The Dynamics of Glutathione Transferases
Drug Metab. Dispos.,
October 1, 2002;
30(10):
1053 - 1058.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Xu, E. S. Lagudah, S. P. Moose, and D. E. Riechers
Tandemly Duplicated Safener-Induced Glutathione S-Transferase Genes from Triticum tauschii Contribute to Genome- and Organ-Specific Expression in Hexaploid Wheat
Plant Physiology,
September 1, 2002;
130(1):
362 - 373.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Desmots, M. Rissel, D. Gilot, D. Lagadic-Gossmann, F. Morel, C. Guguen-Guillouzo, A. Guillouzo, and P. Loyer
Pro-inflammatory Cytokines Tumor Necrosis Factor alpha and Interleukin-6 and Survival Factor Epidermal Growth Factor Positively Regulate the Murine GSTA4 Enzyme in Hepatocytes
J. Biol. Chem.,
May 10, 2002;
277(20):
17892 - 17900.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|